Imugene : Canadian patent granted for HER-Vaxx

Imugene granted Canadian patent for Her-­Vaxx cancer vaccine

• Canadian Patent Office has issued a Grant Notice for Imugene's patent application protecting its cancer vaccine "HER-­Vaxx"
• Patent will protect specific cancer vaccine formulations of commercial interest

July 21, 2017: Imugene Limited (ASX: IMU), an immuno-­oncology company is pleased to announce it has received notice that the Canadian Patent Office has issued a Grant Notice for the Company's proprietary cancer vaccine HER-­Vaxx (Patent no. 2649013 titled "HER-­2/neu multi-­peptide vaccine", 2027 expiry).

HER-­Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease. Gastric cancer patients are currently being enrolled at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

HER-­Vaxx works by targeting the same receptor (and additional receptors) as Herceptin and Perjeta, two of the leading antibody drugs on market, with annual sales of US$8.2 billion.1 Current immunotherapies are predicted to generate sales of US$36 billion by 20252 but costs remain prohibitive for patients. The mechanism of action for HER-­Vaxx may help generate improved efficacy over existing treatments and at a lower cost.

Gastric cancer is a leading cause of cancer death worldwide, representing 10.1% of male cases3. Incidence of gastric cancer is substantially higher in Asia and there is difficulty in accessing current treatments.

For further information please contact:

Leslie Chong, Chief Operating Officer, Imugene

Tel: [phone] (Australia), email: [e-mail] www.imugene.com

Twitter at http://www.twitter.com/TeamImugene.

Sources:

1. $USD Source: Roche Finance Report 2015. http://www.roche.com/dam/jcr:74af99eb-­b51a-­4f13-­88b2-­ aacaf9f53c0c/en/fb15e.pdf

2. Citigroup research note, as reported in http://www.immunotherapyforum.com/blog/deals-­in-­2015-­infographics3 GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.

IMUGENE LIMITED ACN 009 179 551 Phone [phone] Fax [phone] Website www.imugene.com

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-­oncology company headquartered in Melbourne, Australia. Its lead product is HER-­Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-­based immunotherapies against validated and new oncology targets.

HER-­Vaxx is a cancer immunotherapy designed to treat tumours that over-­express the HER-­ 2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-­2/neu. It has been shown in pre-­clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-­2/neu, a well-­known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-­based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-­changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

IMUGENE LIMITED ACN 009 179 551 Phone [phone] Fax [phone] Website www.imugene.com

2